+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
C

Actively Recruiting

Researchers are comparing two treatment approaches for patients with diabetes and significant three-vessel coronary artery disease CAD that does not involve the left main artery. This randomized study aims to evaluate outcomes between imaging- and physiology-guided state-of-the-art percutaneous coronary intervention PCI and coronary artery bypass grafting CABG. The trial focuses on how these methods affect major cardiac and cerebrovascular events in this patient group. Participants will receive either PCI guided by advanced imaging and physiological assessments, including intravascular ultrasound IVUS or optical coherence tomography OCT, and tools like fractional flow reserve FFR or instantaneous wave-free ratio iFR, along with modern drug-eluting stents and optimal medical therapy, or they will undergo standard CABG surgery. Both treatments are delivered under careful clinical protocols, and patients will be followed up extensively to assess various health outcomes. During the study, participants will be monitored for major adverse events over two years and other cardiovascular outcomes over five years. Assessments include hospitalization duration, rehospitalization rates, changes in functional class, quality of life questionnaires, medication use, and healthcare costs. The study aims to provide comprehensive data on the effectiveness and safety of these two revascularization strategies, with participants involved in clinical follow-ups and evaluations throughout the study period.

Age: 20Years +All GendersPhase Not Applicable
39 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
R

Actively Recruiting

Researchers are evaluating a personalized cardiac pacing approach for patients with symptomatic heart failure with preserved ejection fraction HFpEF, where left ventricular ejection fraction is 50% or higher. This interventional, randomized, controlled, double-blinded study aims to compare the safety and effectiveness of dual chamber personalized pacing versus minimal or no pacing in improving heart failure symptoms and health status. Participants will have a qualifying Medtronic dual chamber pacemaker implanted. After implantation and before hospital discharge, they will be randomly assigned to either the treatment group, which receives personalized dual chamber pacing based on their height and baseline LVEF, or the control group, which receives minimal ventricular pacing at a non-personalized rate. Follow-up includes visits at 2, 6, and 12 months, after which the control group will switch to personalized pacing. Additional visits occur at 14, 18, and 24 months, followed by annual long-term monitoring until study completion. During the study, participants will undergo data collection at scheduled visits involving assessments of cardiovascular events, heart failure status using quality of life questionnaires, six-minute walk tests, and blood markers like NT-proBNP. Safety will be monitored for major complications related to the device or procedures for 12 months post-implant. The total participation spans approximately 4.5 years with enrollment over 24 months and follow-up of at least 18 months.

Age: 40Years +All GendersPhase Not Applicable
55 locations
P

Actively Recruiting

Researchers are evaluating the feasibility and preliminary effects of the iSupport-Malaysia program, an online psychoeducational intervention designed for informal caregivers of people living with dementia PLWD in Malaysia. This pilot randomized controlled trial aims to compare the web-based iSupport-Malaysia program with a culturally adapted eBook version. The study focuses on reducing caregiver burden and improving psychological well-being, such as depression, anxiety, stress, and quality of life, among caregivers. Participants will be randomly assigned to either the iSupport-Malaysia web-based intervention or the eBook group. The web intervention includes 23 lessons delivered through videos, quizzes, and reflection exercises on a learning platform, while the eBook group receives a PDF manual with similar content in text and quiz formats. Both groups are expected to complete at least 10 lessons over three months. After the intervention, participants in both groups will have access to both formats, and web group participants may join virtual interviews to share their experiences. Caregivers will complete online assessments at the start, one month, and three months after beginning the program, covering measures of psychological distress and quality of life. The study also tracks feasibility outcomes such as recruitment, retention, randomization, and program engagement. Reminder messages will encourage regular use. The total participation lasts three months, with data collected securely online and interviews conducted via videoconference for feedback.

Age: 18Years - 100YearsAll GendersPhase Not Applicable
4 locations
E

Actively Recruiting

Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.

Age: 40Years +All GendersPhase 3
977 locations
E

Actively Recruiting

Researchers are conducting a Phase III international study to evaluate the effects of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in patients with chronic heart failure HF and impaired kidney function who have recently experienced a heart failure event. The study aims to assess the impact of these treatments on cardiovascular death and heart failure events, including hospitalizations and other HF-related episodes. Participants are randomly assigned to one of three groups one receiving balcinrenonedapagliflozin 15 mg10 mg capsule plus placebo another receiving balcinrenonedapagliflozin 40 mg10 mg capsule plus placebo and a third group receiving dapagliflozin 10 mg tablet plus placebo capsule. All treatments are given once daily orally, alongside standard care for heart failure and kidney impairment. The study is conducted across approximately 700 sites in about 40 countries. During the trial, participants will be monitored over approximately 36 months for cardiovascular death, heart failure hospitalizations, and heart failure events without hospitalization. Assessments include heart failure symptom scores measured at 24 weeks post-randomization. Researchers will also track total occurrences of cardiovascular and heart failure events, as well as overall mortality. This long-term follow-up aims to evaluate treatment effects on these important health outcomes.

Age: 18Years - 130YearsAll GendersPhase 3
852 locations